Patients treated with ciltacabtagene autoleucel (cilta-cel; Carvykti) in the phase 3 CARTITUDE-4 trial (NCT04181827) achieved high rates of progression-free survival (PFS) at near ...
In a phase 1–2 trial, teclistamab, a bispecific antibody targeting CD3 on T-cell surfaces and B-cell maturation antigen on myeloma cells, showed durable responses in heavily pretreated patients with ...
CURE spoke with Dr. Surbhi Sidana about the recently approved antibody-drug conjugate Blenrep for multiple myeloma. On Oct. 23, it was announced that the U.S. Food and Drug Administration (FDA) ...
At age 89, Cal Crow plays water volleyball three days a week, then chases that with a 1,000-foot swim; on his off days, he logs at least a mile around his neighborhood — and that’s with a cancer ...
The FDA has granted accelerated approval to elranatamab-bcmm (Elrexfio) for the treatment of adult patients with relapsed or refractory multiple myeloma who have previously received at least 4 lines ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results